LIVMARLI 9.5 mg/ml, oral solution bottle, 30 ml
Active ingredients: Maralixibat chloride chloride, Maralixibat chloride
Commercialized according to BDPMDispensing in France: Prescription only
Oral solutionbottle, 30 mlorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LIVMARLI 9,5 mg/mL, solution buvable
- Pharmaceutical form
- solution buvable
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polytéréphtalate (PET) jaune(brun) avec fermeture de sécurité enfant de 30 mL + 1 seringue pour administration orale de 0,5 mL + 1 seringue pour administration orale de 1 mL + 1 seringue pour administration orale de 3 mL
- Marketing authorisation holder
- MIRUM PHARMACEUTICALS INTERNATIONAL (PAYS-BAS)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 13 Mar 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
61952616CIP73026495CIP133400930264959Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORURE DE MARALIXIBATsolution | — | SA |
| MARALIXIBATsolution | 9,5 mg · 1 mL de solution | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.